Nirsevimab found Effective in Preventing RSV-Associated Hospitalizations Among Infants in new research
In a significant development in pediatric healthcare, nirsevimab, a long-acting monoclonal antibody, has demonstrated robust real-world effectiveness in protecting infants against respiratory syncytial virus (RSV)-associated hospitalizations, according to an analysis by the New Vaccine Surveillance Network during the period of October 1, 2023, to February 29, 2024.
The report was published in CDC Morbidity and Mortality Weekly Report.
RSV is a major cause of infant hospitalization in the U.S. Nirsevimab, a long-acting antibody, is recommended by CDC for infants and at-risk children. Clinical trials show high efficacy. This analysis provides the first U.S. estimate of post-introduction nirsevimab effectiveness in infants' first RSV season. The CDC's Advisory Committee on Immunization Practices had earlier recommended nirsevimab for infants under the age of 8 months and for children aged 8–19 months at an increased risk for severe RSV disease. This groundbreaking antibody, known for its extended duration of action, emerged from phase 3 clinical trials with an 81% efficacy against RSV-associated lower respiratory tract infections leading to hospitalization within 150 days after receipt.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.